JO2677B1 - Improved process for the preparation of the clevudine compound as an anti-HBV agent - Google Patents

Improved process for the preparation of the clevudine compound as an anti-HBV agent

Info

Publication number
JO2677B1
JO2677B1 JO2007521A JOP20070521A JO2677B1 JO 2677 B1 JO2677 B1 JO 2677B1 JO 2007521 A JO2007521 A JO 2007521A JO P20070521 A JOP20070521 A JO P20070521A JO 2677 B1 JO2677 B1 JO 2677B1
Authority
JO
Jordan
Prior art keywords
clevudine
preparation
improved process
arabinofuranosyl
thymine
Prior art date
Application number
JO2007521A
Other languages
Arabic (ar)
English (en)
Inventor
سوج،كوانج-هو
بارك،هي-كوانج
هان،تاي-هي
كو،تشانج-هوي
سونج-جو وو،
Original Assignee
باكوانج فارم كو.،ال تي دي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by باكوانج فارم كو.،ال تي دي filed Critical باكوانج فارم كو.،ال تي دي
Application granted granted Critical
Publication of JO2677B1 publication Critical patent/JO2677B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JO2007521A 2006-12-08 2007-12-06 Improved process for the preparation of the clevudine compound as an anti-HBV agent JO2677B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020060124497A KR100839322B1 (ko) 2006-12-08 2006-12-08 Ｂ형 간염 치료제 클레부딘의 개선된 제조방법

Publications (1)

Publication Number Publication Date
JO2677B1 true JO2677B1 (en) 2013-03-03

Family

ID=39492283

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2007521A JO2677B1 (en) 2006-12-08 2007-12-06 Improved process for the preparation of the clevudine compound as an anti-HBV agent

Country Status (3)

Country Link
KR (1) KR100839322B1 (ko)
JO (1) JO2677B1 (ko)
WO (1) WO2008069451A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105943547B (zh) * 2016-05-23 2018-01-19 北京慧宝源生物技术股份有限公司 抗hbv的药物组合物及其应用
CN106831901A (zh) * 2016-12-14 2017-06-13 安徽省诚联医药科技有限公司 2‑脱氧‑2‑氟‑1,3,5‑三苯甲酰基‑α‑D‑阿拉伯呋喃糖的制备方法
CN109467583A (zh) * 2018-11-17 2019-03-15 扬州工业职业技术学院 一种克拉夫定的绿色合成工艺

Also Published As

Publication number Publication date
KR100839322B1 (ko) 2008-06-17
WO2008069451A1 (en) 2008-06-12
KR20080052827A (ko) 2008-06-12

Similar Documents

Publication Publication Date Title
EP2609923A3 (en) Nucleoside Phosphoramidates
CL2011001906A1 (es) Compuestos derivados de ribosidos de tieno[3,4-d]pirimidin-7-ilo, y fosfatos de ribosidos; compuestos intermediarios; metodos de preparacion; metodo de tratamiento; composicion farmaceutica; y su uso para tratar una infeccion viral causada por un virus hepatitis c o un virus flaviridae.
HK1125576A1 (en) Hepatitis c virus inhibitors
SG161260A1 (en) Methods for treating infectious disease exacerbated asthma
UA91721C2 (ru) Азеотропная композиция, способ получения е-1,3,3,3-тетрафторпропена, способ его отделения и очищения
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
EP1653976A4 (en) ANTIVIRAL NUCLEOSIDE ANALOGUES AND METHODS FOR TREATING VIRAL INFECTIONS, IN PARTICULAR HIV INFECTIONS
MX2008010611A (es) Derivados de 3-desazapurina como moduladores de receptores similares a toll.
HK1108100A1 (en) Method of heating materials in order to produce objects and device for implementing said method
NZ609146A (en) Modified 4’-nucleosides as antiviral agents
MA32633B1 (fr) Formes cristallines d'un derive 2-thiazolyl-4-quinolinyl-oxy, un inhibiteur puissant du vhc
MX2009008857A (es) Regeneracion termica de arena de fundicion.
WO2002044400A3 (en) Compositions and methods for extracting a nucleic acid
UA92607C2 (ru) СПОСОБ УДАЛЕНИЯ МЕТАЛЛИЧЕСКОГО ОТЛОЖения, содержащего соединения металлов, С ПОВЕРХНОСТИ
MX2007006610A (es) Metodo para simplificar acidos nucleicos microbianos por modificacion quimica de citosinas.
MY151051A (en) Vaccination against dengue virus infection
JO2677B1 (en) Improved process for the preparation of the clevudine compound as an anti-HBV agent
ATE419225T1 (de) Verbundkeramikkörper sowie verfahren zum herstellen eines solchen
CA2608973A1 (en) Processes for treating aluminium dross residues
MXPA03000612A (es) Metodos y procesos mejorados para desinfeccion con yodo.
ATE418405T1 (de) Hochkinetische energie zur bearbeitung von material einsetzendes verfahren
IL190578A0 (en) Vero cell line which is adapted to grow in suspension, method of obtaining same and viral vaccines
IL198801A0 (en) Process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone
TW200730530A (en) Lyophilized compositions of a triazolopyrimidine compound
EP2307040A4 (en) METHOD AND AGENT FOR THE TREATMENT OF VIRUS DISEASES, IN PARTICULAR HIV / AIDS